Literature DB >> 28481152

Aspirin attenuates spontaneous recurrent seizures in the chronically epileptic mice.

Kun Zhu1, Ming Hu1,2, Bo Yuan1, Jian-Xin Liu1, Yong Liu1.   

Abstract

OBJECTIVE: Neuroinflammatory processes are pathologic hallmarks of both experimental and human epilepsy, and could be implicated in the neuronal hyperexcitability. Aspirin represents one of the non-selective nonsteroidal anti-inflammatory drugs with fewer side effects in long-term application. This study was carried out to assess the anti-epileptic effects of aspirin when administered during the chronic stage of temporal lobe epilepsy [TLE] in mice. The alteration of hippocampal neurogenesis was also examined for raising a possible mechanism underlying the protective effect of anti-inflammatory treatment in the TLE.
METHODS: Two months after pilocarpine-induced status epilepticus, the chronically epileptic mice were treated with aspirin (20 mg, 60 mg or 80 mg/kg) once a day for 10 weeks. Spontaneous recurrent seizures were monitored by video camera for 2 weeks. To evaluate the profile of hippocampal neurogenesis, the newly generated cells in the dentate gyrus were labeled by the proliferation marker BrdU. The newborn neurons that extended axons to CA3 area were visualized by cholera toxin B subunit retrograde tracing.
RESULTS: Administration of aspirin with a dosage of 60 mg or 80 mg/kg initiated at 2 months after pilocarpine-induced status epilepticus significantly reduced the frequency and duration of spontaneous recurrent seizures. Aspirin treatment also increased the number of newborn neurons with anatomic integration through improving the survival of the newly generated cells.
CONCLUSION: Aspirin treatment during the chronic stage of TLE could attenuate the spontaneous recurrent seizures in mice. Promotion of hippocampal neurogenesis and inhibition of COX-PGE2 pathway might partly contribute to this anti-epileptic effect. Highlights • Aspirin attenuates spontaneous recurrent seizures of chronically epileptic miceAspirin increases neurogenesis of chronically epileptic hippocampus by improving the survival of newly generated cells • Promotion of hippocampal neurogenesis and inhibition of COX-PGE2 pathway might partly contribute to anti-epileptic effects of aspirin.

Entities:  

Keywords:  Aspirin; epilepsy; hippocampus; inflammation; neurogenesis

Mesh:

Substances:

Year:  2017        PMID: 28481152     DOI: 10.1080/01616412.2017.1326657

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  5 in total

Review 1.  Sleep Disruption Worsens Seizures: Neuroinflammation as a Potential Mechanistic Link.

Authors:  Herlinda Bonilla-Jaime; Helena Zeleke; Asheebo Rojas; Claudia Espinosa-Garcia
Journal:  Int J Mol Sci       Date:  2021-11-20       Impact factor: 5.923

2.  PharmOmics: A species- and tissue-specific drug signature database and gene-network-based drug repositioning tool.

Authors:  Yen-Wei Chen; Graciel Diamante; Jessica Ding; Thien Xuan Nghiem; Jessica Yang; Sung-Min Ha; Peter Cohn; Douglas Arneson; Montgomery Blencowe; Jennifer Garcia; Nima Zaghari; Paul Patel; Xia Yang
Journal:  iScience       Date:  2022-03-10

Review 3.  Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management.

Authors:  Chitra Rawat; Samiksha Kukal; Ujjwal Ranjan Dahiya; Ritushree Kukreti
Journal:  J Neuroinflammation       Date:  2019-10-30       Impact factor: 8.322

4.  Effects of atorvastatin and aspirin on post-stroke epilepsy and usage of levetiracetam.

Authors:  Teng Zhao; Ying Ding; Xuemin Feng; Chunkui Zhou; Weihong Lin
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

5.  The Role of Platelets in the Stimulation of Neuronal Synaptic Plasticity, Electric Activity, and Oxidative Phosphorylation: Possibilities for New Therapy of Neurodegenerative Diseases.

Authors:  Ekaterina Kopeikina; Eugene D Ponomarev
Journal:  Front Cell Neurosci       Date:  2021-07-14       Impact factor: 5.505

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.